Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.
Kathleen N. Moore
No relevant relationships to disclose
Joseph Ponte
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Patricia LoRusso
Employment or Leadership Position - Karmanos Cancer Institute
Michael J. Birrer
No relevant relationships to disclose
Todd Michael Bauer
No relevant relationships to disclose
Hossein Borghaei
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Arisaph Pharmaceuticals; Millennium; Pfizer
David M. O'Malley
No relevant relationships to disclose
Rodrigo Ruiz-Soto
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Robert Lutz
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Research Funding - Immunogen
Laeeq Malik
No relevant relationships to disclose